Research Roundup - June 2026 - First10EM

• MarketBeat’s stock screener tool identified Eli Lilly and Company, Pfizer, and Abbott Laboratories as the top pharmaceutical stocks to watch on June 24th. • These companies are highlighted for their roles in the research, development, manufacturing, and sale of medicines and healthcare products.

• The U.S. Department of Justice announced the 2026 National Health Care Fraud Takedown, charging 455 defendants for their roles in massive fraud and opioid abuse schemes. • The group of defendants includes 90 doctors and other licensed medical professionals who allegedly submitted over $6.5 billion in false health care claims.

• The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule to establish a permanent framework for its Medicare drug price negotiation program. • Scheduled to begin in 2029, the program focuses on negotiating and renegotiating prices for expensive, single-source drugs to reduce costs for millions of patients.

• White House deputy assistant for domestic policy Heidi Overton is reportedly among the final candidates being considered to lead the Food and Drug Administration (FDA). • Overton is a medical doctor who holds a doctorate in clinical investigation from Johns Hopkins University, bringing significant medical and policy expertise to the role.

• The U.S. Department of Health and Human Services (HHS) has launched a coordinated, department-wide initiative to restore American leadership in clinical research. • The ONC is working to integrate clinical trial notifications into electronic health records to connect eligible patients with research opportunities during routine care.

• The author identifies four early-stage medical breakthroughs currently in clinical trials that could potentially treat major killers like cancer, heart disease, and neurodegenerative diseases. • While acknowledging that many promising medical ideas fail during development, these specific advances are being monitored with cautious optimism by leading research institutions.

• The author challenges the public health establishment's claim that universal vaccination is the essential tool for preventing epidemics like Covid-19, polio, and measles. • The piece argues that while medical science is effective at a micro level, a macro-level analysis of epidemic curves is necessary to understand disease trajectories.

• Former leaders from the FDA, CDC, and NIH convened at the BIO International Convention to discuss the dismantling of the Department of Health and Human Services under the Trump administration. • The panel focused on the collapse of existing US public health structures and the urgent need to rebuild a more effective system.

• The SODa-BIC Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group have published new research in The New England Journal of Medicine. • The study, identified by DOI:10.1056/NEJMoa2600526, focuses on clinical trials conducted within intensive care settings.

• The FDA has launched a new initiative aimed at resetting the drug review process to accelerate the development of new medications. • A primary goal of the program is to boost the number of domestic clinical trials, reducing reliance on overseas data and speeding up patient access to therapies.

• PwC reports that health services M&A activity remains active in 2026, with overall deal value increasing compared to the first half of 2025. • Despite higher values, deal volume is slowing as buyers become more selective due to reimbursement pressures and policy uncertainty.